ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
The Oncotype DX® 21-gene recurrence score and clinical outcomes in hormone receptor-positive, HER2-negative male breast cancer: a scoping review.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMale breast cancer (MBC) is a rare malignancy that remains significantly underrepresented in clinical trials. As a result, the clinical utility of Oncotype DX (ODx) 21-gene recurrence score (RS) in men has not been well established. This scoping review aims to systematically examine the current literature regarding the prognostic and predictive role of the ODx in MBC, identify relevant factors that may influence its interpretation, and highlight key research gaps that may hinder its appropriate clinical application in male patients.
methodsA comprehensive literature search was conducted in PubMed and Scopus databases for studies published from 2010 onward. Studies reporting RS results, based on the ODx 21-gene RT-PCR, along with associated clinical outcome, were included.
resultsThree studies evaluating RS in relation to clinical outcomes in MBC met the inclusion criteria. A higher proportion of MBC patients exhibited RS ≥ 31 compared to female breast cancer cohorts. RS showed significant associations with clinical outcomes, including higher mortality rates in high-risk MBC patients. However, in node-negative cases, RS did not retain independent prognostic value. Although RS was prognostically significant in both sexes, outcomes tended to be worse in MBC, particularly in the intermediate- and high-risk groups, where hazard ratios associated with chemotherapy benefit changed minimally after treatment adjustment.
conclusionThe prognostic value of RS in MBC appears evident; however, sex-specific thresholds may be necessary to optimize treatment stratification. Given current data limitations, male-inclusive clinical trials are needed to elucidate the predictive value of RS in men and improve personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.